These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38669092)

  • 21. Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients.
    Mastorino L; Rosset F; Gelato F; Ortoncelli M; Cavaliere G; Quaglino P; Ribero S
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab shows slow, steady effectiveness for intractable prurigo in patients with atopic dermatitis.
    Takeuchi S; Inoue K; Kuretake K; Kiyomatsu-Oda M; Furue M
    J Dermatol; 2021 May; 48(5):638-644. PubMed ID: 33742710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
    Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis.
    Clabbers J; Boesjes C; Spekhorst L; van Gisbergen MW; Maas E; Marshall J; Janssen R; Janssen M; Zuithoff N; Steijlen P; de Graaf M; van Geel M; de Bruin-Weller M; Gostyński A
    J Allergy Clin Immunol; 2024 Apr; 153(4):1155-1161.e4. PubMed ID: 38272373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.
    Bosma AL; Ouwerkerk W; Heidema MJ; Prieto-Merino D; Ardern-Jones MR; Beattie P; Brown SJ; Ingram JR; Irvine AD; Ogg G; Patel P; Reynolds NJ; Hearn RMR; Wan M; Warren RB; Woolf RT; Hyseni AM; Gerbens LAA; Spuls PI; Flohr C; Middelkamp-Hup MA;
    JAAD Int; 2023 Mar; 10():14-24. PubMed ID: 36387062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
    Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Dupilumab in Children 6 Months to 11 Years Old With Atopic Dermatitis: A Retrospective Real-World Study in China.
    Yang N; Ye Y; Shao J; Wu H; Xu Q; Zhu J; Liu J; Li Z
    Dermatitis; 2024; 35(S1):S39-S46. PubMed ID: 36800177
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
    O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
    Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials.
    Penton H; Jayade S; Selveindran S; Heisen M; Piketty C; Ulianov L; Jabbar-Lopez ZK; Silverberg JI; Puelles J
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2549-2571. PubMed ID: 37747670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice.
    Jang DH; Heo SJ; Jung HJ; Park MY; Seo SJ; Ahn J
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32599878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis.
    Stander S; Kim BS; Guillemin I; Rhoten S; Wratten S; Brookes E; O'Malley JT; Bansal A; Msihid J; Thomas R; Bahloul D
    J Eur Acad Dermatol Venereol; 2024 Jul; 38(7):1401-1409. PubMed ID: 38329222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients.
    Barei F; Zussino M; Tavecchio S; Angileri L; Rizzo A; Calzari P; Marzano AV; Ferrucci S
    Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
    Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.
    Kwatra SG; Yosipovitch G; Ständer S; Guillemin I; Msihid J; Bansal A; Makhija M; Wiggins S; Zahn J; Thomas RB; Bahloul D
    J Eur Acad Dermatol Venereol; 2024 Oct; 38(10):1965-1972. PubMed ID: 38785405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Instrumental evaluation of skin barrier function and clinical outcomes during dupilumab treatment for atopic dermatitis: An observational study.
    Cristaudo A; Pigliacelli F; Sperati F; Orsini D; Cameli N; Morrone A; Mariano M
    Skin Res Technol; 2021 Sep; 27(5):810-813. PubMed ID: 33651467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topical tacrolimus during systemic therapy for severe atopic dermatitis in the clinical practice.
    Ferrucci SM; Angileri L; Marzano AV; Berti E; Tavecchio S
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2518-2523. PubMed ID: 35442467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study.
    Ureña-Paniego C; Montero-Vílchez T; Sanabria-de-la-Torre R; Soto-Moreno A; Molina-Leyva A; Arias-Santiago S
    Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.